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Background: Fusarochromanone (FC101) is a small molecule fungal metabolite with a host of interesting biological
functions, including very potent anti-angiogenic and direct anti-cancer activity.
Results: Herein, we report that FC101 exhibits very potent in-vitro growth inhibitory effects (IC50 ranging from
10nM-2.5 μM) against HaCat (pre-malignant skin), P9-WT (malignant skin), MCF-7 (low malignant breast), MDA-231
(malignant breast), SV-HUC (premalignant bladder), UM-UC14 (malignant bladder), and PC3 (malignant prostate) in
a time-course and dose-dependent manner, with the UM-UC14 cells being the most sensitive. FC101 induces
apoptosis and an increase in proportion of cells in the sub-G1 phase in both HaCat and P9-WT cell lines as
evidenced by cell cycle profile analysis. In a mouse xenograft SCC tumor model, FC101 was well tolerated,
non-toxic, and achieved a 30% reduction in tumor size at a dose of 8 mg/kg/day. FC101 is also a potent
anti-angiogenenic agent. At nanomolar doses, FC101 inhibits the vascular endothelial growth factor-A
(VEGF-A)-mediated proliferation of endothelial cells.
Conclusions: Our data presented here indicates that FC101 is an excellent lead candidate for a small molecule
anti-cancer agent that simultaneously affects angiogenesis signaling, cancer signal transduction, and apoptosis.
Further understanding of the underlying FC101’s molecular mechanism may lead to the design of novel targeted
and selective therapeutics, both of which are pursued targets in cancer drug discovery.
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Fusarochromanone (FC101) is a mycotoxin that is pro-
duced by the symbiotic fungus, Fusarium equiseti, found
on decaying cereal plants from northern latitudes. FC101
was originally discovered to cause avian tibial dyschon-
droplasia (ATD) in broiler chickens [1,2]. It also reduced
hatchability in fertile eggs when birds were fed diets con-
taining Fusarium-infected feed [1,3]. This toxin is also sus-
pected of being involved in etiopathogenesis of Kashin-
Beck disease in children from northern China, Siberia, the
former USSR, and Korea [4]. Lee et al. first isolated this
molecule and determined its structure (without stereo-
chemistry) via NMR and mass spectrometry [5]. FC101 is* Correspondence: emahdavi@lsus.edu
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article, unless otherwise stated.distinguished from other known chromanone natural
products by the unique arrangement of the alternating
β-keto-amine functionality along its upper face and two
geminal methyl groups at C(2) (Figure 1). Using X-Ray
crystallography, the absolute stereochemistry at C(3') was
defined as 3’-R, according to the Cahn-Inglold-Prelog con-
vention (Smith, unpublished observations). The amine
group at C (3’) on the side-chain is in fact important to
the molecule’s biological activity, since its acetylation dras-
tically reduces the activity [6]. Wuthier reported that
FC101’s inhibition of calcification in the legs of baby
chickens was likely the result of its anti-angiogenic activity
[7]. This effect is associated with a thickening of the car-
tilage on the tibial growth plate and a failure of this tissue
to vascularize and calcify.
In addition to its anti-angiogenic properties in chic-
kens, FC101 is also a potent anti-angiogenic agent intral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Structure of fusarochromanone (FC101).
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man microvascular endothelial cells (NCI, unpublished).
Those initial cell studies were done in the absence of
any angiogenic factors.
It was later discovered that FC101 also acts directly on
cancer cells. A 60-cell-line drug screening assay performed
by the National Cancer Institute (NCI) revealed that
FC101 inhibited the proliferation of 35 of 58 human can-
cer cell lines with IC50’s of less than 100 nM [NCI, un-
published]. The most sensitive cell lines were human
melanoma, small cell lung carcinoma, and colon adeno-
carcinoma, with IC50 values all below 10 nM. The NCI
also conducted a COMPARE screen on FC101. This
screen applies algorithms that are used to assess the mode
of action of a test compound. In this screen, FC101 inhib-
ition was studied in the same 60 cell-line drug screening
assay as mentioned above. These patterns were then com-
pared to those found in a library of over 50,000 com-
pounds. The data generated from the COMPARE test is
represented as a Pearson correlation coefficient. Cor-
relations greater the 0.8 indicate that the test molecule in-
hibits cellular growth in a similar manner to a compound
found in the NCI database. Correlations below 0.6 are
thought to have minimal, if not altogether different modes
of action. The NCI COMPARE correlation factor for
FC101 was 0.475, indicating that FC101 is unique in its
mode of action [NCI, unpublished].
Another unique attribute of FC101 is its intrinsic fluo-
rescence, with a maximum excitation at 385 nm and emis-
sion at 457 nm. A recent study utilized this intrinsic
fluorescence to investigate the kinetics and uptake of
FC101 by tumorigenic cells vs. normal cells in a rodent
model analyzed by confocal microscopy [8]. This study
reported an increased uptake of FC101 and growth inhi-
bition in tumorgenic B16 melanoma and MCF-7 breast
adenocarcinoma cells, as compared to the normal cardiac
fibroblast cells. This group also reported experimental and
in-silico values for a series of physiochemical properties
(LogP, LogD, polar surface area, hydrogen bonding,molecular flexibility) that contribute to the bioavailability
of FC101. They concluded that FC101 shows very good
cell permeability and intestinal absorption, meeting the
criteria for therapeutic drugs that were established by
Lipinski et al. [9-11].
In this study we also tested the hypothesis that FC101’s
molecular targets (i.e., interacting biomolecules) could be
regulators of angiogenesis, cancer signal transduction, cell
proliferation, and/or programmed cell death (apoptosis).
The detailed effects of FC101 on these processes were
determined for a panel of human tumor cell types (skin
squamous cell carcinoma [SCC], breast, prostate, and
bladder). In addition, we tested the tumor suppressive ef-
fect of FC101 in vivo, in a mouse tumorigenicity model,
against human skin SCC cells. SCC is the most aggressive
form of non-melanoma skin cancer.
Results
It was previously reported in a mouse xenograft model
for melanoma that FC101 induced expression of active
caspase-3 [12]. Furthermore, our preliminary studies in
yeast have shown that Yca1 is involved in the response
to FC101-treatment (Williams-Hart, unpublished). Yca1
is a caspase-like protein that has been shown to be
important for executing apoptotic-like responses in yeast
[13]. This finding led to the hypothesis that the tumor
suppressive effects of FC101 may result from changes in
the regulation of apoptotic signaling. In order to deter-
mine whether FC101 can induce cell death in culture, a
preliminary indicator of apoptosis, several cell lines de-
rived from different human tumor types were treated
with a range of doses of FC101 over a course of four
days. The MTT cell viability assay was used to obtain an
indirect measure of cell number. All tumor cell types
were sensitive to FC101 in a dose dependent manner,
and in the case of the breast and bladder cancer cell
lines, the more malignant cells were more sensitive to
FC101 than the less malignant ones (Figure 2, compare
100 nM curves in panel C to D, and E to F).
These results are more clearly indicated in Figure 2H,
where the percent growth inhibition for all 7 cell lines is
shown for the day 4 time point (color of lines in graphs in
Figure 2A-G corresponds to color of bars in Figure 2H).
The UM-UC14 cells were the most sensitive of all of the
cell lines; the 100nM dose drastically diminished cell
number compared to other cells lines. It should be noted
that this was the fastest growing cell line of the group
tested (Figure 2F, compare the y-axis scale to the other
graphs).
Since the MTT assay only measures cell metabolism/
mitochondrial respiration, which is an indirect measure of
cell number, it cannot readily determine whether reduced
cell number is caused by suppression of proliferation, or

















Figure 2 Comparison of the dose-response and time-response impact of FC101 treatment on cell viability of seven cell lines. A-G: A540
is the absorbance at 540 nm, which positively correlates with cell number. Error bars are shown for triplicate cultures. The graphs are representative of
at least three experiments having similar results. H: The percent growth inhibition at day 4, calculated as (A540C-A540T/A540)x100, where A540C is the
control value and A540T is the treated value. The graph lines in A-G are color matched to the bars in H.
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effect on the cell cycle distribution. The HaCat premalig-
nant keratinocyte and P9 WT skin SCC cell lines were
chosen for this analysis, because these cell lines have been
extensively studied in this context with other apoptosis-
inducing drugs.
Cells were treated for 24 and 48 hours with FC101
(10 μM). These time points were chosen because marked
effects of FC101 on viability were first detected after
48 hours of treatment (Figure 2A and B, compare 1 and 2
day time points). As with the MTT results for both cell
lines, there was little effect of FC101 treatment after
24 hours (Figure 3, upper row, FC101 panels). However,
after 48 hours there were fewer attached cells in both cell
lines, with a stronger effect visible for the P9 WT cells(Figure 3, lower panels). The presence of many rounded
cells detaching from the plate is an indicator of cell death,
possibly by apoptosis. In order to verify whether FC101
did indeed induce apoptosis, and whether there were any
changes in the proliferative behavior of the cells, FACS
analysis was performed for the same dose and time points
of treatment. Treatment with FC101 for 24 hours caused
an increase in percentage of cells in the 2 N DNA content
peak, indicating cells in the G2 and M phases of the cell
cycle for both cell lines (Figure 4, compare FC101 panels
to controls in top row). The G2 phase is the point at
which the DNA has been fully replicated, but prior to
mitosis. This effect was accompanied by a modest increase
in the percentage of particles that were smaller in size
than G1 cells (the sub-G1 fraction) for both cell lines,
Figure 3 Cells were plated at a density of 1.5 × 106 cells/10 cm plate and treated the following day with 10 μM FC101. Cells were
photographed on a phase contrast microscope at 100X magnification.
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An enhanced fraction of cells in the 2 N peak was still
observed after 48 hours of treatment, but the sub-G1
fraction was markedly increased compared to controls
(Figure 4, lower panels). The increase in the percentage of
cells in the 2 N peak was greater at both time points for
the HaCaT cells compared to SRB12-p9 cells. However,Figure 4 Differential effect of FC101 on cell cycle distribution and ap
and treated as in described in Figure 3 and harvested for FACS analysis. Y-a
staining. The numbers in boxes indicate the percentages of live cells in eac
are sub-G1 in size are also indicated.the induction of apoptosis, as measured by the size of the
sub-G1 fraction, was greater for the SRB12-p9 cells.
Programmed cell death can proceed through either
caspase-dependent or independent routes [14]. To deter-
mine the mechanism of FC101-induction of apoptosis,
MDA-MB-231 breast cancer cells were exposed to
FC101 (0–1 μM) for 24 h, followed by western blottingoptosis induction in HaCaT and SRB12-p9 cells. Cells were plated
xis indicates cell number, X-axis indicates intensity of propidium iodide
h phase of the cell cycle. The percent of total particles counted that
Figure 6 MDA-MB-231 cells, grown in 6-well plates, were
treated with FC101 (0–1 μM) for 24 h, followed by western
blotting with antibodies to anti-apoptotic proteins (Bcl-2,
Bcl-XL, Mcl-1) and pro-apoptotic proteins (BAD, BAK, BAX).
Beta-tubulin was used for loading control. Immunoblots shown are
representative of three independent experiments that showed
similar results.
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of the pro-apoptotic, anti-apoptotic, and caspase pro-
teins involved in apoptosis.
FC101 induces the cleavage of both caspase-3 and
PARP, a well-known substrate for activated caspases
(Figure 5). This indicates that FC101 activates the cas-
pase signaling cascade. However, FC101 does not affect
the expression of the anti-apoptotic proteins, Bcl-2, Bcl-
XL, Mcl-1, or the pro-apoptotic proteins BAD, BAK,
BAX (Figure 6). Thus, although FC101 activates apop-
tosis in a caspase-dependent manner, this activity does
not involve a mitochondrial-mediated intrinsic mecha-
nism. Furthermore, treatment with FC101 increases the
activity of caspase-8, thus substantiating that FC101 ini-
tiates apoptotic cascades through a death receptor medi-
ated extrinsic mechanism involving caspase-8 activation
(Figure 5).
Mitogen Activated Protein Kinases (MAPKs) are also
involved in programmed cell death [15] and are frequently
implicated in apoptotic responses by small molecule
chemotherapeutic agents. Next, we determined whether
FC101-induced cell death involves MAPKs, namely activa-
tion of Erk1/2 and p38 downstream pathways. For this,
HeLa cells were exposed to FC101 (0–1 μM) for 48 hours,
followed by immunoblot analysis. As shown in Figure 7,
FC101 did not affect phosphorylation of ERK1/2, but
induced phosphorylation of p38 in a concentration-
dependent manner. Note: p-ERK1/2 level is often corre-
lated to increased cell survival, whereas phosphorylated
p38 level is frequently associated with stress response or
cell death. This could suggest that FC101 induction of
cancer cell death is in part due to the activation of the p38
MAPK signaling pathway.
The mTOR signaling pathway also plays a central role
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Figure 5 MDA-MB-231 cells, grown in 6-well plates, were
treated with FC101 (0–1 μM) for 24 h, followed by western
blotting with antibodies to cleaved caspase-3, cleaved caspase
8, and cleaved PARP. Beta-tubulin was used for loading control.
Immunoblots shown are representative of three independent
experiments that showed similar results.Inhibition of mTOR by rapamycin downregulates cyclin
D1 expression [17] and Rb phosphorylation [18], resul-
ting in cell cycle arrest during the G1-G0 phase. Since
we found that FC101 arrests cells in G1-G0 phase of the
cell cycle, we hypothesized that the cell-cycle modula-
tory effect of FC101 is linked to inhibition of the mTOR
pathway. To test this hypothesis, we examined the ef-
fects of FC101 on mTOR signaling in Hela cells. As
shown in Figure 7, FC101 lowers the levels of p-4E-BP1
(T37/46), one of the best-characterized downstream ef-
fector molecules of mTOR [16] in a concentration-
dependent manner.
It is clear that the anti-proliferative and pro-apoptotic
effects of FC101 are mediated through both the activa-
tion of p38-MAPK and the inhibition of mTOR sig-
naling pathways. Further investigation of the underlying
molecular mechanisms may lead to the design of other
novel small molecules targeting both the mTOR and
MAPK pathways.
Figure 7 HeLa cells, grown in 6-well plates, were treated with
FC101 (0–1 μM) for 72 h, followed by western blotting with
antibodies for p-4E-BP1 (Thr37/Thr46) phospho-Erk1/2 (Thr202/
Tyr204), p38, phospho-p38 (Thr180/Tyr182). Beta-tubulin was
used for loading control. Immunoblots shown are representative of
three independent experiments that showed similar results.
Figure 8 The growth inhibitory effect of FC101 on the MCF-7
and MDR MCF-7/Dox cells.
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drug resistant (MDR) cells, MCF-7/Dox. We found that
FC101 has a more pronounced anti-cancer effect (~8-
fold lower IC50) on MCF-7/Dox than on their parental
cell line, MCF-7 (Figure 8). The MCF-7/Dox cells over-
express two major genes responsible for drug resistance,
one of which is glycosylceramide synthase (GCS) [19].
The fact that FC101 displays greater potency towards
MDR cells suggests that it should be further explored as
a sensitizing agent that may offer a therapeutic advan-
tage. We are also currently designing experiments to
more fully elucidate the detailed mechanism underlying
this favorable feature of FC101.
Like most other bioactive natural flavonoids, FC101 has
modest in-vivo activity. In a mouse xenograft skin SCC
tumor model, FC101 was well tolerated and non-toxic,
but it required a dose of 8 mg/kg/day treatment to achieve
a 30% reduction in tumor size, compared to untreated
controls (Figure 9, compare pink line with blue line).
To assess the direct anti-angiogenic properties of
FC101, we used the MS1 mouse microvascular endo-
thelial cell line, which was selected for its high VEGFR2
expression and responsiveness to VEGF functions [20].Thus, these cells are a good in-vitro proxy for optimal
VEGF dependent responses that would be seen in vivo.
FC101 displayed potent growth inhibition of MS1 cells
with an IC50 < 50 nM after 4 hours treatment. The dose-
dependent effect of FC101 on VEGF-stimulated MS1 cell
growth was also examined using an ELISA-based BrdU
incorporation assay. We determined that FC101 signifi-
cantly inhibits VEGF-dependent endothelial cell proli-
feration at all doses beginning at 10 nM (Figure 10).
Discussion
FC101 is a small molecule fungal metabolite that has
very potent anti-angiogenic activity and direct anti-
cancer activity, and it exhibits potent in-vitro growth in-
hibitory effects (IC50 < 2.5 μM for all cell lines tested).
However, the precise biological target of FC101 remains
unknown.
The data show that FC101 has the potential to be an ef-
fective anti-cancer therapeutic drug, because it suppresses
both angiogenesis and tumorigenesis. In-vitro and in-vivo
observations both indicate that FC101 is a powerful cyto-
toxic agent with strong selectivity towards cancer cells
versus normal cells. Its broad-spectrum inhibitory effect
on cancer cell lines and its direct inhibition of endothelial
cell growth suggest that it could be beneficial for treating
a variety of human cancers. In-vitro experiments showed
significant differential sensitivity in a variety of malignant
cell types (e.g., melanoma) vs. pig-1 melanocytes, im-
mortalized non-malignant skin cells that serve as a control
for human melanoma cell lines8. Cellular proliferation was
measured by 3H-thymidine incorporation (cpm/well).
FC101 inhibited greater than 90% of incorporation with as
little as 10 nM in melanoma cells. In contrast, normal
Figure 9 Immunocompromised mice (SCID) were injected subcutaneously with 1x106 SRB12-p9 cells on day 0, and injected
intraperitoneally with 8 mg/kg/day FC101 dissolved in PBS, or PBS alone as a control. The tumor volumes were determined by caliper
measurement on the days indicated.
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100-fold; data are not shown). In fact, FC101 dosages of
0.1 and 1 ng/mL caused stimulation of melanocyte proli-
feration; inhibition occurred only after exposure to high
levels of FC101 for prolonged period of time, 8–12 days.
An in vivo mouse xenograft SCC tumor model has also
shown that FC101 is well tolerated and non-toxic to
normal animal tissues.
Another unique attribute of FC101 was its differential
growth inhibitory effect towards chemotherapy-resistant
cancer cells. FC101 displayed a very potent sub-micromo-
lar IC50 value against the MDR cells, MCF-7/Dox, which
overexpress the enzyme, GCS. GCS converts ceramide to
glucosylceramide, thereby deactivating it. Ceramide is an
important lipid second messenger that mediates growth
arrest and apoptosis of cells. Ceramide-induced apoptosis
contributes to the therapeutic efficiencies of anthra-
cyclines, taxanes, cytokines, and irradiation, and the over-
expression of GCS has been identified as a possibleFigure 10 Suppression of VEGF-induced proliferation of mouse
microvascular endothelial cells (MS1).mechanism for resistance to chemotherapy in a number
of human cancers [19]. Indeed, GCS overexpression is dis-
played in MDR cell lines of breast, ovarian, cervical, and
colorectal cancers [16]. Furthermore, these same inves-
tigators have demonstrated that inhibition of GCS sensi-
tizes MDR cells to anticancer drugs [19,21]. Inhibition of
GCS with small molecules, such as D-threo-1-phenyl-2-
decanoylamino-3-morpholino-1–propanol (PDMP), sensi-
tizes cancer cells to doxorubicin, paclitaxel and vincristine
[22]. The suppression of GCS expression by MBO-asGCS
restores ceramide signaling (particular C18-ceramide)
during the course of doxorubicin treatment, thereby pro-
moting caspase-executed apoptotic death in cells. Thus,
targeting GCS would promote caspase-executed apoptotic
signaling mediated by ceramide, thereby eliminating tu-
mors with poor response to conventional chemotherapy,
such as doxorubicin. However, a therapeutic agent that ef-
ficiently inhibits GCS in vivo remains to be developed.
FC101 is a promising candidate for such an agent. Our
future studies will address whether FC101 suppresses
GCS expression or activity to reverses drug resistance.
Figure 4 illustrates that FC101 has at least one other
beneficial biological effect besides apoptosis induction.
The increased fraction of cells in the 2 N DNA content
peak G2 and M phases of the cell cycle suggests that
FC101 could slow the rate of cell proliferation, possibly
through an effect on the transition from G2 to mitosis.
Further experiments, such as detailed analysis of cell
cycle protein levels and phosphorylation states as well as
cytological observation of treated cells using DNA stai-
ning, will be necessary to distinguish between cells in
G2 and M phase.
We have shown that FC101’s molecular mode of action
involves three key cellular mechanisms including, extrinsic
apoptosis, MAPK, and mTOR signaling pathways. FC101
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in the final stages of apoptosis. Increased PARP cleavage
confirms the activation of the caspase cascade. FC101 also
activates caspase-8, as evidenced by increased caspase-8
cleavage, further substantiating that FC101 induces apop-
tosis through an extrinsic pathway.
FC101 does not affect the expression of the anti-
apoptotic proteins, Bcl-2, Bcl-XL, Mcl-1, or the pro-
apoptotic proteins BAD, BAK, BAX. This indicates that
FC101’s induction of apoptosis does not occur through
an intrinsic mechanism. The data support the notion
that FC101 induces caspase-dependent apoptosis, which
implies that the extrinsic pathway is involved in this
process. Future experiments will explore the effects of
FC101 on the expression of death-receptor signaling
proteins (TNF-α and FAS) to further confirm that
FC101-induction of apoptosis is death receptor mediated
through an extrinsic pathway.
FC101 did not affect phosphrorylation of ERK1/2, but it
induced phosphorylation of p38 MAPK in a concen-
tration-dependent manner (HeLa cells, 0–1 μM). Note
p-ERK1/2 levels are often correlated to increased cell sur-
vival, whereas p38 levels are frequently associated with
stress response or cell death. In addition, FC101 inhibits
the phosphorylation of 4E-BP1 (T37/46), a substrate of
mTOR. Since mTOR is a master kinase that controls cell
growth and survival, this suggests that FC101 may induce
cell death by simultaneously activating p38 MAPK and
inhibiting mTOR signaling.
We have found that the cell-permeable small mole-
cule, FC101, affects a diverse group of biological targets
involved in cellular signal transduction. Collectively, our
findings suggest that FC101 induces a series of caspase-
dependent events in the extrinsic cascade, resulting in
apoptosis, and we have shown that FC101 simulta-
neously affects two downstream protein substrates
involved in two distinct kinase signaling pathways
(mTOR and MAPK signaling pathways).
We believe that FC101 holds promise as an anticancer
agent due to its unique molecular mechanism especially
as a modulator of both mTOR and MAPK, two master
kinases that regulate cell proliferation and growth [16].
Further elucidation of the underlying molecular mecha-
nism may lead to the design of a new class of targeted
cancer therapeutics.
Our data also shows that FC101 inhibits VEGF-
dependent proliferation of microvascular endothelial
cells (MS1 cells), indicating a strong anti-angiogenic ef-
fect. As shown in Figure 10, all doses of FC101 signifi-
cantly inhibited VEGF-mediated Brdu incorporation.
One limitation of prior work is that it was performed in
the absence of any endothelial cell growth factors. This
made it unclear how effective FC101 would be in
conjunction with a growth factor like VEGF.FC101 has shown high potency in vitro, coupled with
low toxicity toward normal tissues and little or no ad-
verse effects in various animal studies. In one report on
the use of FC101 in a melanoma xenograft model in
mice, Dréau et al. commented on the potent cytotoxicity
of FC101, but also noted only minimal anti-angiogenic
activity, despite the strong activation of caspase-3 at the
periphery [12]. This model also confirmed other pre-
vious reports that FC101 is less potent in-vivo than
in-vitro. Identifying the pharmacokinetic parameters of
biologically active compounds is an essential step in the
development of potential drug candidates. Typical phar-
macokinetics parameters are the in vivo absorption, dis-
tribution, metabolism, and elimination of compounds in
blood and tissues over time. FC101 is a flavonoid, and
over 4,000 natural compounds have been characterized
as such. These molecules are usually poorly to mode-
rately water-soluble. They are also rapidly metabolized
and degraded in vivo. Flavonoids generally bind tightly
to serum proteins (e.g., serum albumin) and thus
substantial amounts are inaccessible to the desired bio-
logical targets.
Through a previous study in Dr. Wuthier’s lab (one of
our collaborators), we have seen that FC101 does indeed
bind to BSA with a binding constant of 2.47 ± 0.17 x 108.
To achieve efficacy in vivo, promising preclinical drug
candidates like FC101 need to exploit pharmacologic de-
livery routes that facilitate sustained release of the active
form of the drug at the desired site of action. Incor-
poration of flavonoids into lipid- or polymer-based
nanoparticles appears promising. This markedly helps
drug delivery, as these nanoparticles can protect the
drug from degradation in the gastrointestinal tract and
degradation from first-pass metabolism in the liver, by
virtue of the unique absorption mechanism of these
conjugates through the lymphatic system.
Thus, although we view FC101 as a promising drug
candidate for structure-based lead optimization, its
stability, bioavailability, and in vivo distribution appear
to be sub-optimal. Currently, we are synthesizing new
FC101 analogs with greater in-vivo potency and also
attempting to identify the precise biological target(s) of
FC101.
Conclusion
Scientists have traditionally turned to nature to find new
lead compounds for fighting disease. Fungus and molds
have produced many important new lead compounds for
drug development. That is how FC101 was discovered,
and it represents an important new lead compound for
the treatment of cancer. However, the precise biological
targets of FC101 remain unknown. Thanks to advances
in computer-based assays and chemical synthesis, there
are new ways to predict a drug’s mechanism of action
Mahdavian et al. BMC Research Notes 2014, 7:601 Page 9 of 11
http://www.biomedcentral.com/1756-0500/7/601and to synthesize more biologically active analogs of
promising lead compounds. The chemical synthesis of
novel analogs, cell-based as well as protein-based assays
that probe specific signaling pathways will play a signifi-




FC101 in its free base form (MW 292.3) was isolated
and purified from Fusarium equiseti (originally supplied
by Dr. Xie at the University of Minnesota). This fungus
is found exclusively in the arctic latitudes and grown on
rice cultures by Dr. Brian Furmanski. FC101 was then
crystallized in the presence of phosphoric acid to form
the more stable phosphate salt form (MW 390.3). Its
purity (>98%) was confirmed by 1H-NMR, 13C-NMR,
and UV–vis spectroscopy.
Cell lines and culture
Seven human tumor cell lines were used in this study.
HaCat (pre-malignant skin, a gift from Prof. N.E. Fusenig,
Deutsches Krebforschungszentrum), SRB12-p9 (malignant
skin SCC, a gift from Dr. Reuben Lotan, Univ. of Texas-
MD Anderson Cancer Center), MCF-7 (low malignant
mammary gland adenocarcinoma), MDA-231 (malignant
mammary gland adenocarcinoma), SV-HUC (premalig-
nant bladder), UM-UC14 (malignant bladder, a gift from
Dr. H.B. Grossman, Univ. of Texas-MD Anderson Cancer
Center), and PC3 (malignant, prostate). MCF-7, MDA-
231, SV-HUC and PC3 cells were obtained from the
American Type Culture Collection (Manassas, VA).
HaCaT cells were cultured in 4x modified Eagle’s medium
(MEM) media (1.4 mM Ca2+), supplemented with 5% fetal
calf serum (FCS) and 1% Penicillin Streptomycin Solution
(Pen-Strep). SRB12-p9, MCF-7, MDA-MB231, and PC3
cells were cultured in Dulbecco’s MEM (DMEM)/F12
medium containing 10% FCS and 1% Pen-Strep. UM-
UC14 cells were cultured in 50% DMEM/F12 media and
50% DMEM low glucose media containing 10% FCS and
1% Pen-Strep. SV-HUC cells were cultured in HyQ
Ham’s/F-12 media with 7% FCS and 1% Pen-Strep. For
passaging, subconfluent cells were incubated with 0.1%
trypsin/2 mM EDTA and suspended in media before
replating. All cells were cultured at 37°C in the humidified
atmosphere of 5% CO2/95% air.
MTT assays
Cell viability was determined by the MTT 3-(4, 5-
dimethyltiazol 2-yl)-2,5-diphenyltetraolium bromide assay.
Briefly, cells were plated in triplicate wells at varying den-
sities (1,000 cells/well for HaCaT, SRB12-p9, MCF7,
MDA-MB231; 1,500 cells/well for MCF7, PC3; 2,000
cells/well for SV-HUC) in 100 μl growth media in 96-wellplates and treated with the FC101 at the concentrations
indicated in Figure 4. After a range of treatment times a
solution of MTT (20 μl of a 12 mM solution in PBS) was
added and incubated for 2 hours at 37°C. The cells were
washed gently with PBS, and 100 μl of DMSO was then
added to the wells followed by mild shaking to dissolve
the MTT precipitate. Absorbance at a wavelength of 540
nm was measured for each well using a Wallac Victor3
1420 Multilabel multi-well plate reader (Perkin-Elmer).
Cell viability assays for multi-drug resistant MCF-7/Dox
cells
Cell viability was analyzed by quantitation of ATP, an indi-
cator of active cells, using the CellTiter-Glo luminescent
cell viability assay (Promega, Madison, WI). Briefly, cells
(4,000 cells/well) were grown in 96-well plates with 10%
FBS RPMI-1640 medium for 24 hr. FC101 was introduced
into cells by Lipofectamine 2000 (vehicle control) in Opti-
MEM I reduced-serum medium, for a 4 hr incubation.
Cells were then incubated with increasing concentrations
of FC101 in 5% FBS medium for an additional 72 hr. Cell
viability was determined by the measurement of lumines-
cent ATP in a Synergy HT microplate reader, following
incubation with CellTiter-Glo reagent. Triplicate experi-
ments were repeated two times.
Cell cycle analysis
The cell cycle profile was determined by cell cycle flow cy-
tometry based on cellular DNA content, using an Epics
Profile II cell sorter (Coulter Electronics, Inc.). Cells were
treated with FC101 or DMSO vehicle control for the
indicated durations, trypsinized, collected and pelleted to-
gether with any material floating in the medium. Cells
were fixed in cold 70% ethanol, resuspended in PBS at a
density of > 106 cells/ml followed by RNase A (1 mg/ml)
treatment, addition of propidium iodide (20 μg/ml final
concentration) and analysis by flow cytometry. The per-
centage of cells in different phases of the cell cycle were
determined from the raw data using the ModFit V3.2.1
flow cytometry software. Apoptosis was assessed by deter-
mining the amount of sub-G1 sized particles.
Western blot analysis
Western blotting was carried out as described previously
[14]. Briefly, control and treated cells (0–10 μM) were
washed twice with cold PBS and then lysed in the lysis
buffer [50 mmol/L Tris, pH 7.2; 150 mmol/L NaCl; 1%
sodium deoxycholate; 0.1% SDS; 1% Triton X-100; 10
mM NaF, 1 mM Na3VO4; Protease inhibitor cocktail
(1:1000 dilution, Sigma). Lysates were sonicated for 10
seconds and centrifuged at 13,000 X g for 10 minutes at
4°C. Protein concentration was determined using the
BCA assay (Protein Assay Kit, Pierce). Protein samples
(~40 μg) were electrophoresed on 8–12% SDS-PAGE,
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probed with respective primary and secondary anti-
bodies. The following primary antibodies were used:
p38, phospho-p38 (Thr180/Tyr182), PARP, Bcl-2, Mcl-1,
surviving, (all from Santa Cruz Biotechnology), Bcl-xL,
BAK, BAX (Biomedia), p-4E-BP1(Thr37/Thr46), caspase
3, cleaved caspase 3, cleaved caspase 8, BAD, phospho-
Erk1/2 (Thr202/Tyr204; Cell Signaling), and β-tubulin
(Sigma). Goat anti-mouse Ig-G-horseradish peroxidase
(HRP), goat anti-mouse IgM-HRP, and goat anti-rabbit
IgG-HRP were purchased from Pierce.
Anti-angiogenesis assay
For our anti-angiogenic assays we used the murine MS1
microvascular endothelial cell line, selected due to its
high VEGFR2 expression and responsiveness to VEGF.
Inhibition of MS1 cell proliferation in the presence and
absence of VEGF was evaluated using DNA incorpo-
ration of BrdU. MS-1 cells were serum starved overnight
and the next morning preincubated with various concen-
trations of FC101 for 30 minutes. Next, 50 ng/ml VEGF
or PBS alone (i.e., control) was added to respective wells
along with BrdU and incubated for 4 hours. Cells were
then fixed and BrdU incorporation measured by ELISA.
In vivo tumorigenicity assay
All animal studies were carried out following the USDA,
PHS, and NIH animal use and care guidelines. The animal
protocol was approved by the Institutional Animal Care and
Use Committee at the Louisiana State University Health
Science Center in Shreveport (LSUHSC-S) (Protocol Num-
ber, P10-045). SCID Beige mice (CB17/Icr.Cg-Prkdcsci-
dLystbg/Crl) were maintained on AIN76A semi-purified diets
(Dyets, Bethlehem, PA). Mice were administered FC101 or
PBS by IP injections 5 days per week. Total daily drug intake
was 8 mg/kg. On day 3, groups of 8 mice (6–7 week old)
were injected subcutaneously (s.c.) in the dorsal region with
1 × 106 SRB12-p9 cells in 0.1 ml PBS. Tumors were mea-
sured five times weekly by digital caliper using the formula
V= ((W+L)/4))3 × 4/3π, where L = length and W=width.
Tumors were harvested and bisected at 25 days post-
injection, or at the time of attaining a volume of 2 cm3.
Tumors were fixed in formalin for histological analysis.
The differences between the groups of mice in terms of
tumor volume or persisting benign cysts was compared
using the Mann–Whitney test and differences in latency
to tumor formation and survival were calculated by the
Log-rank test and Kaplan-Meier Cumulative Survival tests.
Statistical analysis
Statistical analyses were completed using ANOVA, fol-
lowed by Fisher's protected least significant difference
procedure. A p-value of < 0.05 (2-tail) was considered
statistically significant.Abbreviations
FC101: Fusarochromanone; VEGF-A: Vascular endothelial growth factor-A.
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